Skip to main content

Treatment Clinical Trials for Small Cell Lung Cancer

Review the small cell lung cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 92

Valemetostat and Atezolizumab for the Treatment of Extensive-Stage Small Cell Lung Cancer
Status: Active
Location: 2 locations
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Status: Active
Location: 2 locations
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Status: Active
Location: 2 locations
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Lamivudine in Combination with Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Fingolimod for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Niraparib and Dostarlimab for the Treatment of Brain Metastases in Patients with Advanced Cancers, STARLET Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Total Body Irradiation and Hypofractionated Radiation Therapy with Atezolizumab and Chemotherapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, TESSERACT Trial
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Tarlatamab in Combination with Standard of Care Radiation Therapy for the Treatment of Relapsed or Refractory of DLL3-Expressing Small Cell Lung Cancers and other High Grade Neuroendocrine Cancers
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Cirtuvivint and Irinotecan for the Treatment of Relapsed Small Cell Lung Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
RAPA-201 Therapy of Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Genetically Modified Immune Cells (iC9-GD2.CAR.IL-15 T Cells) for the Treatment of Extensive Stage Small Cell Lung Cancer or Stage IV Non-small Cell Lung Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Status: Active
Location: 2 locations
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of ZN-c3 in Participants With Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland